<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00309777</url>
  </required_header>
  <id_info>
    <org_study_id>NK-104-302</org_study_id>
    <secondary_id>EudraCT number 2005-001033-15</secondary_id>
    <nct_id>NCT00309777</nct_id>
  </id_info>
  <brief_title>Study to Compare the Efficacy and Safety of Pitavastatin and Simvastatin</brief_title>
  <official_title>Study of Pitavastatin Vs. Simvastatin (Following Up-Titration) in Patients With Primary Hypercholesterolemia or Combined Dyslipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kowa Research Europe</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kowa Research Europe</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy and safety of pitavastatin with that of
      simvastatin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">October 2006</completion_date>
  <primary_completion_date type="Actual">October 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From Baseline in Low Density Lipoprotein-cholesterol (LDL-C) at 12 Weeks</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>National Cholesterol Education Program (NCEP) LDL-C Target Attainment</measure>
    <time_frame>12 week</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">857</enrollment>
  <condition>Hypercholesterolemia</condition>
  <condition>Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>Pitavastatin 2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pitavastatin 2 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Simvastatin 20 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Simvastatin 20 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pitavastatin 4 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pitavastatin 4 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Simvastatin 40 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Simvastatn 40 mg once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pitavastatin</intervention_name>
    <description>Pitavastatin once daily</description>
    <arm_group_label>Pitavastatin 2 mg</arm_group_label>
    <arm_group_label>Pitavastatin 4 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>Simvastatin once daily</description>
    <arm_group_label>Simvastatin 20 mg</arm_group_label>
    <arm_group_label>Simvastatin 40 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females (18-75 years)

          -  Must have been following a restrictive diet

          -  Diagnosis of primary hypercholesterolemia or combined dyslipidemia

        Exclusion Criteria:

          -  Homozygous familial hypercholesterolemia or familial hypoalphalipoproteinemia;

          -  Conditions which may cause secondary dyslipidemia.

          -  Uncontrolled diabetes mellitus (by hemoglobin A1c [HbA1c] &gt; 8%)

          -  Abnormal serum creatine kinase (CK) above the pre-specified level

          -  Abnormal pancreatic, liver or renal function

          -  Significant heart disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dragos Budinski, Med Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Medical Director</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Geri-Med Oy</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaisaniemen Laakariasema</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keravan Laakarikeskus</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SOK-tyoterveyshuolto</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TYKS University Hospital</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento Di Medicina Clinica e Biotecnologia Applicata</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro di Ricerca Clinica</name>
      <address>
        <city>Chieti</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gerontologia e Geriatria - Universita degli Studi</name>
      <address>
        <city>Ferrara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Medicina Interna DIMI</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita di Modena e Reggio Emilia, Policlinico</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Medicina Clinica e Sperimentale</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicina Clinica e delle Patologie Emergenti</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Medicina Interna e Scienze Biomediche</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O Malattie Metaboliche e Diabetologia</name>
      <address>
        <city>Treviglio</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria</name>
      <address>
        <city>Trieste</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Volvat Medisinske Senter</name>
      <address>
        <city>Fredrikstad</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nyomen Legekontor</name>
      <address>
        <city>Kongsberg</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radhuset Spesialistsenter</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rikshospitalet - University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skedsmo Medisinske Senter A.S.</name>
      <address>
        <city>Skedsmokorset</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kemerovo Cardiology Dispensary</name>
      <address>
        <city>Kemerovo</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Clinical Hospital 1 of RZD</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital 23</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital 64</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow City Clinical Hospital 68</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Research Center for Preventive Medicine</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novosibirsk Reg. Clinical Cardiology Dispensary</name>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Medical Unit 122, St. Pb</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital of Russian Academy of Sciences</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consulting and Diagnostic Center 85</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krestovsky Island Medical Institute</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pokrovskaya City Hospital</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Michael's Partnership</name>
      <address>
        <city>Bath</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Avondale Surgery</name>
      <address>
        <city>Chesterfield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Knowle House Surgery</name>
      <address>
        <city>Plymouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Burngreave Surgery</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Helier Hospital</name>
      <address>
        <city>Surrey</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Box Surgery</name>
      <address>
        <city>Wiltshire</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastleigh Surgery</name>
      <address>
        <city>Wiltshire</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lovemead Group Practice</name>
      <address>
        <city>Wiltshire</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Chad's Surgery</name>
      <address>
        <city>Wiltshire</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Health Centre</name>
      <address>
        <city>Wiltshire</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Italy</country>
    <country>Norway</country>
    <country>Russian Federation</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2005</study_first_submitted>
  <study_first_submitted_qc>March 31, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2006</study_first_posted>
  <results_first_submitted>August 26, 2009</results_first_submitted>
  <results_first_submitted_qc>November 13, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 16, 2009</results_first_posted>
  <last_update_submitted>January 7, 2010</last_update_submitted>
  <last_update_submitted_qc>January 7, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2010</last_update_posted>
  <responsible_party>
    <name_title>Neil Hounslow, MD</name_title>
    <organization>Kowa Research Europe, Ltd.</organization>
  </responsible_party>
  <keyword>hypercholesterolemia</keyword>
  <keyword>kowa</keyword>
  <keyword>dyslipidemia</keyword>
  <keyword>pitavastatin</keyword>
  <keyword>NK-104</keyword>
  <keyword>Primary Hypercholesterolemia or Combined Dyslipidemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Pitavastatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were randomized to one of 4 treatment arms based on inclusion/exclusion criteria.</recruitment_details>
      <pre_assignment_details>After a 6-8 week run in period when no lipid lowering therapy was allowed, subjects were randomized to one of 4 treatment arms.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Pitavastatin 2 mg</title>
          <description>Pitavastatin 2 mg once daily</description>
        </group>
        <group group_id="P2">
          <title>Simvastatin 20 mg</title>
          <description>Simvastatin 20 mg once daily</description>
        </group>
        <group group_id="P3">
          <title>Pitavastatin 4 mg</title>
          <description>Pitavastatin 4 mg once daily</description>
        </group>
        <group group_id="P4">
          <title>Simvastatin 40 mg</title>
          <description>Simvastatn 40 mg once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="315"/>
                <participants group_id="P2" count="108"/>
                <participants group_id="P3" count="323"/>
                <participants group_id="P4" count="111"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="311">All randomized patients who received at least one dose of study treatment.</participants>
                <participants group_id="P2" count="107">All randomized patients who received at least one dose of study treatment.</participants>
                <participants group_id="P3" count="320">All randomized patients who received at least one dose of study treatment.</participants>
                <participants group_id="P4" count="110">All randomized patients who received at least one dose of study treatment.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="292"/>
                <participants group_id="P2" count="99"/>
                <participants group_id="P3" count="304"/>
                <participants group_id="P4" count="107"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pitavastatin 2 mg</title>
          <description>Pitavastatin 2 mg once daily</description>
        </group>
        <group group_id="B2">
          <title>Simvastatin 20 mg</title>
          <description>Simvastatin 20 mg once daily</description>
        </group>
        <group group_id="B3">
          <title>Pitavastatin 4 mg</title>
          <description>Pitavastatin 4 mg once daily</description>
        </group>
        <group group_id="B4">
          <title>Simvastatin 40 mg</title>
          <description>Simvastatn 40 mg once daily</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="311"/>
            <count group_id="B2" value="107"/>
            <count group_id="B3" value="320"/>
            <count group_id="B4" value="110"/>
            <count group_id="B5" value="848"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Data presented are for the safety population, defined as all randomized patients who receive at least one dose of the study drug.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="214"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="231"/>
                    <measurement group_id="B4" value="76"/>
                    <measurement group_id="B5" value="593"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="89"/>
                    <measurement group_id="B4" value="34"/>
                    <measurement group_id="B5" value="255"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>Data presented are for the safety population, defined as all randomized patients who receive at least one dose of the study drug.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.7" spread="8.83"/>
                    <measurement group_id="B2" value="58.6" spread="9.64"/>
                    <measurement group_id="B3" value="57.7" spread="8.97"/>
                    <measurement group_id="B4" value="58.4" spread="9.54"/>
                    <measurement group_id="B5" value="58.3" spread="9.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Data presented are for the safety population, defined as all randomized patients who receive at least one dose of the study drug.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="196"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="195"/>
                    <measurement group_id="B4" value="48"/>
                    <measurement group_id="B5" value="502"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="115"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="125"/>
                    <measurement group_id="B4" value="62"/>
                    <measurement group_id="B5" value="346"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in Low Density Lipoprotein-cholesterol (LDL-C) at 12 Weeks</title>
        <description>Percent change from baseline in low density lipoprotein-cholesterol (LDL-C)after 12 Weeks</description>
        <time_frame>Baseline to 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pitavastatin 2 mg</title>
            <description>Pitavastatin 2 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Simvastatin 20 mg</title>
            <description>Simvastatin 20 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Pitavastatin 4 mg</title>
            <description>Pitavastatin 4 mg once daily</description>
          </group>
          <group group_id="O4">
            <title>Simvastatin 40 mg</title>
            <description>Simvastatn 40 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Low Density Lipoprotein-cholesterol (LDL-C) at 12 Weeks</title>
          <description>Percent change from baseline in low density lipoprotein-cholesterol (LDL-C)after 12 Weeks</description>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="307"/>
                <count group_id="O2" value="107"/>
                <count group_id="O3" value="319"/>
                <count group_id="O4" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.99" spread="14.573"/>
                    <measurement group_id="O2" value="-34.97" spread="15.528"/>
                    <measurement group_id="O3" value="-43.97" spread="14.494"/>
                    <measurement group_id="O4" value="-42.84" spread="15.769"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>National Cholesterol Education Program (NCEP) LDL-C Target Attainment</title>
        <description>Number of subjects achieving National Cholesterol Education Program (NCEP) LDL-C Target (LDL less than or equal to 130 mg/dL)at Week 12</description>
        <time_frame>12 week</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Pitavastatin 2 mg</title>
            <description>Pitavastatin 2 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Simvastatin 20 mg</title>
            <description>Simvastatin 20 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Pitavastatin 4 mg</title>
            <description>Pitavastatin 4 mg once daily</description>
          </group>
          <group group_id="O4">
            <title>Simvastatin 40 mg</title>
            <description>Simvastatn 40 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>National Cholesterol Education Program (NCEP) LDL-C Target Attainment</title>
          <description>Number of subjects achieving National Cholesterol Education Program (NCEP) LDL-C Target (LDL less than or equal to 130 mg/dL)at Week 12</description>
          <population>Full Analysis Set</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="307"/>
                <count group_id="O2" value="107"/>
                <count group_id="O3" value="319"/>
                <count group_id="O4" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="215"/>
                    <measurement group_id="O2" value="69"/>
                    <measurement group_id="O3" value="253"/>
                    <measurement group_id="O4" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Pitavastatin 2 mg</title>
          <description>Pitavastatin 2 mg once daily</description>
        </group>
        <group group_id="E2">
          <title>Simvastatin 20 mg</title>
          <description>Simvastatin 20 mg once daily</description>
        </group>
        <group group_id="E3">
          <title>Pitavastatin 4 mg</title>
          <description>Pitavastatin 4 mg once daily</description>
        </group>
        <group group_id="E4">
          <title>Simvastatin 40 mg</title>
          <description>Simvastatn 40 mg once daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 8.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="320"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Pleuropericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="320"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Campylobacter intestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="320"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="320"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="320"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 8.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="320"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="320"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="320"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="320"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="320"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="320"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="320"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="320"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="320"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="320"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Neil Hounslow</name_or_title>
      <organization>Kowa Research Europe, Ltd.</organization>
      <phone>01189229004</phone>
      <email>nhounslow@kowa.co.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

